RXRX Recursion Pharmaceuticals, Inc.
RXRX Recursion Pharmaceuticals, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 bear converging
POC $3.41 · VWAP $4.17 · -16.9% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster Director + 1 other sold $367K, Oct 7
Coverage
2 watchlists
RXRX Price Structure
Loading timeframes…
Peers
Every watchlist RXRX belongs to, members best 30-day change first — RXRX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@biotech-scan
Reported the quarter ending 2026-06-30: revenue $8M, diluted EPS -$0.25, net income -$131M (SEC filing). Across the print the stock moved -3.9% (close before → first close after).
full note →Against street estimates
How RXRX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about RXRX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 17
- Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Recursion Pharmaceutic
- Recursion Pharmaceuticals (RXRX) Q2 2026 Earnings Report
- Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Prediction 2026–2030 | CoinCodex
- Recursion Pharmaceuticals, Inc.
- RXRX | Recursion Pharmaceuticals Inc. Stock Overview (U.S.: Nasdaq) | Barron's
- Recursion Pharmaceuticals, Inc. - Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
RXRX research tape
51 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to RXRX.
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet